A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Kalunian, Kenneth; Furie, Richard; F. Morand, Eric; N Bruce, Ian; Manzi, Susan; Tanaka, Yoshiya; Winthrop, Kevin; Hupka, Ihor; Zhang, Lijin; Werther, Shanti; Abreu, Gabriel; Hultquist, Micki; Tummala, Raj; Lindholm, Catharina; Al‐Mossawi, Hussein

doi:10.1002/art.42392

Public

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Published in Arthritis & Rheumatology • Nov 11, 2022

Authors:

Kenneth Kalunian

Richard Furie

Eric F. Morand

Abstract

OBJECTIVE: To explore long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP) trial and enrolled in the placebo-controlled 3-year long-term ext...

Subject

Tolerability

Placebo

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!